LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

LAmbre™ LAA Closure System Obtaining Approval for Investigator-initiated Pre-market Clinical Research in the US

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 24 December 2020, the Group's LAmbre™ Left Atrial Appendage (LAA) Closure System ("**LAmbre™ LAA Closure System**" or the "**Device**") obtained approval by the US Food and Drug Administration ("**FDA**") for the commencement of an investigator-initiated clinical trial ("**Trial**") in the US, and the Group will charge a reasonable price for the Device. The primary objective of the Trial is to demonstrate the safety and efficacy of the implantation of the Device in patients with large and/or irregularly shaped appendages with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism.

LAmbre™ LAA Closure System has been self-developed by the Company over the past decade and has advanced in product design and technology within the industry. The Device has previously already obtained investigational device exemption application approval from the FDA (which was sponsored by the Group) on 15 May 2019. The obtaining of approval for the investigator-initiated Trial can provide additional clinical data to support the market-entry process for the Device in the US.

The Device has currently achieved satisfactory sales performance in the Chinese and European markets and is gradually entering the Southeast Asia and Latin America markets. The Company is confident that the Device will obtain US market-entry approval from the FDA after completing pre-market clinical research in the US.

As the LAmbre™ LAA Closure System is still subject to further approval from the FDA, shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 30 December 2020

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng and Mr. FU Feng being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.